PawCostsLongevity Atlas
Search atlasHealthspan outlook
Atlas / Interventions / Undenatured type II collagen for dog mobility
dog · joint supplement

Undenatured type II collagen for dog mobility

Controlled dog studies report mobility or pain outcomes, but formulations and comparators differ and no lifespan benefit was tested.

small controlled canine studies; no longevity endpoint
Short answer

A mobility evidence topic—not a pet-longevity proof or a reason to copy a study dose.

The atlas separates a biological hypothesis, a canine or feline measurement, a controlled clinical result and a commercial longevity claim. They are not interchangeable.

Evidence records

What was actually measured?

Orthopedic Examination And Load Mobility Score

randomized controlled prospective active-comparator study

A randomized controlled prospective study compared UC-II with robenacoxib in dogs affected by osteoarthritis.

Population and result

60 client-owned dogs randomized between two active groups · the study evaluated change over 30 days; it was not a placebo-controlled longevity trial

Limitation

Short duration, active comparator, diagnosed OA population and no survival outcome.

Mobility, Pain And Joint-Metabolism Measures

randomized double-blind placebo-controlled crossover study

A later double-blind placebo-controlled crossover study tested a combination of UC-II and Boswellia.

Population and result

17 randomized dogs with mild or moderate OA from 60 screened dogs · combination-product outcomes cannot establish the effect of UC-II alone

Limitation

Small randomized sample and multi-ingredient product.

Dose and safety boundary

No human-to-pet conversion.

Policy

No dose is provided. Product formulation, diagnosis, concurrent medicines and safety require veterinary review.

US regulatory context

“Pet supplement” is not a universal legal category.

FDA does not recognise a separate dietary-supplement category for animal products; depending on intended use, products are regulated as animal food or animal drugs. Disease-treatment or prevention claims can indicate new-animal-drug intent.

Open FDA source →
Sources and conflicts

Trace every material statement.

Evaluation of undenatured type II collagen compared with robenacoxib in dogspeer-reviewed primary clinical study · 2019 · DOI 10.3390/vetsci6030072Open source →
UC-II and Boswellia in mild or moderate mobility disorders in dogspeer-reviewed randomized crossover trial · 2024Open source →A branded combination product was studied; the record does not generalize to all collagen supplements.

Page data version: 2026-08-18. Medical review is not claimed without a named sign-off.